Sevabertinib is a reversible kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2) and exhibits activity against epidermal growth factor receptor (EGFR). It is indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, and received accelerated FDA approval in November 2025.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing Sevabertinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Ceftobiprole medocaril sodium
pharmaceutical raw material
Flurogestone acetate
pharmaceutical raw material
Trans-itraconazole
pharmaceutical raw material
Eribulin
pharmaceutical raw material
The international HS code for Sevabertinib (CAS 2521285-05-0) is 2934.99.
2934.99
2934 99 90
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
3-(3-chloro-2-methoxyanilino)-2-[3-[[(2S)-1,4-dioxan-2-yl]methoxy]-4-pyridinyl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one
VYQVHWNNPKOJEA-AWEZNQCLSA-N
COC1=C(C=CC=C1Cl)NC2=C(NC3=C2C(=O)NCC3)C4=C(C=NC=C4)OC[C@@H]5COCCO5
Sourcing Sevabertinib?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.